Thursday, June 11, 2026

Intelligence Β· INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,797
Companies 1,769
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Showing page 127 of 200 Β· By data quality, then INN

  1. idecabtagene vicleucel

    ABECMA

    EMA: approved

    L01
  2. igovomab

    INDIMACIS 125

    EMA: withdrawn

    V09IB03
  3. imetelstat

    RYTELO

    EMA: approved

    L01XX80
  4. imipenem

    RECARBRIO

    EMA: approved

    J01DH56
  5. imlifidase

    IDEFIRIX

    EMA: approved

    L04AA
  6. imlunestrant

    INLURIYO

    EMA: approved

    L02BA
  7. inclisiran

    LEQVIO Novartis Pharmaceuticals

    EMA: approved Β· TGA: approved

    C10AX
  8. indacaterol

    ONBREZ Novartis Pharmaceuticals

    EMA: approved Β· TGA: approved

    R03AK
  9. indinavir

    CRIXIVAN

    EMA: withdrawn

    J05AE02
  10. inebilizumab

    UPLIZNA

    EMA: approved

    L04AA
  11. infigratinib

    FEBSELTIQ

    EMA: application withdrawn

    L01E
  12. infliximab

    INFLECTRA Pfizer Australia Pty Ltd

    FDA: approved Β· EMA: approved Β· TGA: approved Β· PMDA: approved Β· NMPA: clinical trials

    L04AB02
  13. influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)

    PANDEMRIX

    EMA: unknown

    J07BB02
  14. influenza vaccine (h1n1)v (whole virion, vero cell derived, inactivated)

    CELVAPAN

    EMA: withdrawn

    J07BB01
  15. influenza vaccine (live attenuated, nasal)

    FLUENZ TETRA

    EMA: approved

    J07BB03
  16. influenza vaccine (split virion, inactivated)

    INTANZA

    EMA: withdrawn

    J07BB02
  17. influenza vaccine (surface antigen, inactivated, adjuvanted)

    FLUAD TETRA

    EMA: approved

    J07BB02
  18. influenza vaccine (surface antigen, inactivated, prepared in cell cultures)

    FLUCELVAX

    EMA: approved

    J07BB02
  19. influenza vaccine h1n1v (surface antigen, inactivated, adjuvanted)

    FOCETRIA

    EMA: unknown

    J07BB02
  20. inotersen

    TEGSEDI

    EMA: approved

    N07
  21. inotuzumab ozogamicin

    BESPONSA Pfizer Australia Pty Ltd

    FDA: approved Β· EMA: approved Β· TGA: approved Β· PMDA: approved

    L01FB01
  22. insulin glulisine

    APIDRA Sanofi-aventis Healthcare Pty Ltd

    EMA: approved Β· TGA: approved

    A10AB06
  23. insulin human (rdna)

    ACTRAPHANE

    EMA: approved

    A10AD01
  24. interferon alfa-2a

    ALPHEON

    EMA: refused

    L03AB04

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles β€” INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page β€” it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.